Key Highlights

  • VivoSim Labs (NASDAQ:VIVS) traded at USD 0.1597, up 5.07%, in pre-market trading on Tuesday, October 27, 2026, with no company-specific announcement; shares outstanding rose from 3,194,295 on June 30, 2026 to 13,390,789 on August 3, 2026.
  • Nexentis Technologies Inc. (NASDAQ:NXTS) traded at USD 0.5154, down 8.34%, after a release of Monday, October 26, 2026 reporting a completed computational screening stage at its subsidiary MitoCareX Bio, with no financing announced.
  • DataMeds AI (NASDAQ:MEDS) traded at USD 2.06, down 5.76%, after an announcement of Thursday, October 22, 2026 that Datavault AI signed a non-binding letter of intent for a 19.9% equity stake tied to an expanded technology licence.
  • Lunai Bioworks (NASDAQ:LNAI) traded at USD 0.26, down 5.45%, after the company disclosed on Thursday, October 22, 2026 that Nasdaq trading is expected to be suspended on Friday, October 30, 2026.

VivoSim Labs (NASDAQ:VIVS): tissue models funded by warrants

VivoSim Labs (NASDAQ:VIVS), a San Diego based services company that tests drug candidates in three-dimensional human liver and intestine tissue models, is the biotech tools name of the group. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move. The most recent disclosure reviewed is the Form 8-K of Thursday, August 6, 2026, which reported compliance with a Nasdaq equity rule, a milestone payment from Eli Lilly and Company and a July financing. The advance appears consistent with thin pre-market liquidity, in which a small number of orders can shift a low-priced quote by several points. That reading is an inference, not a reported cause.

For the fiscal first quarter ended June 30, 2026, the company reported revenue of USD 18,000 and a net loss of USD 1.3 million, or USD 0.25 per share, according to the earnings summary. Cash was approximately USD 10.1 million as of Monday, August 3, 2026, reflecting a USD 5.0 million milestone payment and USD 1.0 million of escrow release from Eli Lilly received on Wednesday, July 22, 2026, plus a financing of Friday, July 17, 2026 with gross proceeds of USD 4.0 million at USD 0.85 per underlying share. The quote sits well below that price by simple arithmetic, and the company reiterated an expectation of fiscal 2027 revenue growth above 500%, measured from a very small base.

Nexentis Technologies (NASDAQ:NXTS): an AI screening result that awaits proof

Nexentis Technologies Inc. (NASDAQ:NXTS) is the only name here that couples an AI label with a solar and post-harvest business. In the release, MitoCareX Bio completed the initial computational screening stage of an initiative with Boltz, and the findings are described as not experimentally validated, which limits their evidential weight. Simple arithmetic on the snapshot implies a prior close near USD 0.5623, and the decline appears consistent with thin liquidity in a very small float. October releases covered cloud deployment on Monday, October 7 and bioinformatics hiring on Monday, October 12, 2026, which appears consistent with spending ahead of any revenue.

The quarterly report filed on Thursday, August 13, 2026 for the period ended June 30, 2026 contains a going concern disclosure, meaning a statement that substantial doubt exists about continuing operations. Borrowings at that date comprised loans payable of USD 1.739 million, a line of credit of USD 207 thousand and short-term borrowings of USD 215 thousand. The bull reading is that the screening stage and the Google Cloud infrastructure show progress at a very small capitalisation of about USD 817 thousand. The bear reading is that no revenue is attributed to the new initiative, so dilution and a share price below USD 1.00 are named risks.

DataMeds AI (NASDAQ:MEDS): a non-binding equity letter against a stockholders' deficit

DataMeds AI (NASDAQ:MEDS), formerly Wellgistics Health, an integrated healthcare company combining pharmacy services, telemedicine and artificial intelligence platforms, is the healthcare AI case. The most recent company-specific news was the announcement that Datavault AI signed a non-binding letter of intent to acquire the stake in consideration of an expanded technology licence. This account relies on the announcement titles rather than the full text. A non-binding letter creates no obligation to close, and the decline appears consistent with profit-taking and thin pre-market liquidity.

The company's release of Monday, August 17, 2026 reported net revenues of USD 1,779,860 for the second quarter of 2026, against USD 7,790,865 a year earlier, although revenue rose 14% from the first quarter. The net loss was USD 18,363,225, or USD 7.13 per share. Cash was USD 2,456,373 at June 30, 2026, against total liabilities of USD 52,263,663 and a stockholders' deficit of USD 19,504,231. The company raised USD 6.5 million in June 2026 and completed a 1-for-50 reverse split in May 2026. Lock-up agreements covering 1,533,930 common shares, about 49% of shares outstanding, were scheduled to run at least 90 more days.

Lunai Bioworks (NASDAQ:LNAI): the listing, not the science, drives the tape

Lunai Bioworks (NASDAQ:LNAI), a company developing AI-enabled discovery platforms, preclinical cell and gene therapy programmes and biodefence tools, reported a Nasdaq delisting determination in its release of Thursday, October 22, 2026. The company stated that it plans to delist voluntarily and deregister and will not request a hearing, and delisting is expected on or about Thursday, November 12, 2026. Nasdaq cited a stockholders' deficit of USD 9,024,946 against a USD 2,500,000 minimum. The pre-market decline appears consistent with holders reducing positions before the suspension, an inference from the timing. No over-the-counter quotation is planned.

For the fiscal year ended June 30, 2026, revenue was USD 51,992, all from one research-services customer, and the net loss was USD 3,562,479, helped by a gain of about USD 12.0 million on a bankruptcy. Cash was USD 1,713,653, the working capital deficit was USD 16,874,093 and the filing carries going concern language. The bull reading rests on a collaboration with BrainStorm Therapeutics, signed on Tuesday, August 4, 2026, targeting an initial Parkinson's data readout in the first half of 2027, and on an NIH STTR grant of USD 1.85 million. The bear reading is that cash is nearly exhausted and the shares will lose their exchange listing.

Where Things Stand

The answer is that the AI label is moving these four names far less than their balance sheets and listing positions. VivoSim Labs (NASDAQ:VIVS) pairs growth targets with sharp dilution. Nexentis (NASDAQ:NXTS) offers computational results that await experimental proof. DataMeds AI (NASDAQ:MEDS) depends on a non-binding equity letter set against a stockholders' deficit, while Lunai Bioworks (NASDAQ:LNAI) is leaving the exchange for lack of equity.

The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, which follows the rate rise of Wednesday, September 16, 2026, the Lunai trading suspension on Friday, October 30, 2026 and a definitive Datavault AI agreement, with closing expected in the second half of 2026. VivoSim Labs and Nexentis have no announced dates for their next filings. Pre-market prices are thinly traded snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.